Artículos de revistas
A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease
Fecha
2013-01Registro en:
Laderach, Diego Jose; Gentilini, Lucas Daniel; Giribaldi, María Laura; Cardenas Delgado, Victor Manuel; Nugnes, Lorena Gisela; et al.; A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease; American Association for Cancer Research; Cancer Research; 73; 1; 1-2013; 86-96
0008-5472
CONICET Digital
CONICET
Autor
Laderach, Diego Jose
Gentilini, Lucas Daniel
Giribaldi, María Laura
Cardenas Delgado, Victor Manuel
Nugnes, Lorena Gisela
Croci Russo, Diego Omar
Al Nakouzi, Nader
Sacca, Paula Alejandra
Casas, Gabriel
Mazza, Osvaldo Néstor
Shipp, Margaret A.
Vazquez, Elba Susana
Chauchereau, Anne
Kutok, Jeffery L.
Rodig, Scott J.
Elola, Maria Teresa
Compagno, Daniel Georges
Rabinovich, Gabriel Adrián
Resumen
Galectins, a family of glycan-binding proteins, influence tumor progression by modulating interactions between tumor, endothelial, stromal, and immune cells. Despite considerable progress in identifying the roles of individual galectins in tumor biology, an integrated portrait of the galectin network in different tumor microenvironments is still missing. We undertook this study to analyze the "galectin signature" of the human prostate cancer microenvironment with the overarching goal of selecting novel-molecular targets for prognostic and therapeutic purposes. In examining androgen-responsive and castration-resistant prostate cancer cells and primary tumors representing different stages of the disease, we found that galectin-1 (Gal-1) was the most abundantly expressed galectin in prostate cancer tissue and was markedly upregulated during disease progression. In contrast, all other galectins were expressed at lower levels: Gal-3, -4, -9, and -12 were downregulated during disease evolution, whereas expression of Gal-8 was unchanged. Given the prominent regulation of Gal-1 during prostate cancer progression and its predominant localization at the tumor-vascular interface, we analyzed the potential role of this endogenous lectin in prostate cancer angiogenesis. In human prostate cancer tissue arrays, Gal-1 expression correlated with the presence of blood vessels, particularly in advanced stages of the disease. Silencing Gal-1 in prostate cancer cells reduced tumor vascularization without altering expression of other angiogenesis-related genes. Collectively, our findings identify a dynamically regulated "galectin-specific signature" that accompanies disease evolution in prostate cancer, and they highlight a major role for Gal-1 as a tractable target for antiangiogenic therapy in advanced stages of the disease.